LLY

1,014.81

-1.98%↓

JNJ

202.44

-1.54%↓

ABBV

228.37

-0.49%↓

UNH

333.06

-1.2%↓

AZN

90.22

-0.61%↓

LLY

1,014.81

-1.98%↓

JNJ

202.44

-1.54%↓

ABBV

228.37

-0.49%↓

UNH

333.06

-1.2%↓

AZN

90.22

-0.61%↓

LLY

1,014.81

-1.98%↓

JNJ

202.44

-1.54%↓

ABBV

228.37

-0.49%↓

UNH

333.06

-1.2%↓

AZN

90.22

-0.61%↓

LLY

1,014.81

-1.98%↓

JNJ

202.44

-1.54%↓

ABBV

228.37

-0.49%↓

UNH

333.06

-1.2%↓

AZN

90.22

-0.61%↓

LLY

1,014.81

-1.98%↓

JNJ

202.44

-1.54%↓

ABBV

228.37

-0.49%↓

UNH

333.06

-1.2%↓

AZN

90.22

-0.61%↓

Search

TransMedics Group Inc

Abierto

SectorSanidad

138.01 -1.72

Resumen

Variación precio

24h

Actual

Mínimo

133.52

Máximo

140.66

Métricas clave

By Trading Economics

Ingresos

-11M

24M

Ventas

-14M

144M

P/B

Media del Sector

59.221

80.03

Margen de beneficios

16.909

Empleados

728

EBITDA

-13M

33M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+3.5% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

625M

5.1B

Apertura anterior

139.73

Cierre anterior

138.01

Noticias sobre sentimiento de mercado

By Acuity

43%

57%

138 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

TransMedics Group Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2025, 19:15 UTC

Principales Movimientos del Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Comparación entre iguales

Cambio de precio

TransMedics Group Inc previsión

Precio Objetivo

By TipRanks

3.5% repunte

Estimación a 12 Meses

Media 145 USD  3.5%

Máximo 170 USD

Mínimo 115 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para TransMedics Group Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

8

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

92.43 / 94.18Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

138 / 374 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat